These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36630897)

  • 41. Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis.
    Suzuki T; Kusumoto S; Yamashita T; Masuda A; Kinoshita S; Yoshida T; Takami-Mori F; Takino H; Ito A; Ri M; Ishida T; Komatsu H; Ueda M; Ando Y; Inagaki H; Iida S
    Ann Hematol; 2016 Jan; 95(2):279-85. PubMed ID: 26555284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.
    Fenoglio R; Baldovino S; Ferro M; Sciascia S; Rabajoli G; Quattrocchio G; Beltrame G; Naretto C; Rossi D; Alpa M; Barreca A; Papotti MG; Roccatello D
    J Nephrol; 2021 Feb; 34(1):231-240. PubMed ID: 32472525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:
    Bianchi G; Zhang Y; Comenzo RL
    JACC CardioOncol; 2021 Oct; 3(4):467-487. PubMed ID: 34729520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
    Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
    Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis.
    Garcia Y; Collins AB; Stone JR
    Hum Pathol; 2018 Feb; 72():71-79. PubMed ID: 29133141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AL-Kappa Primary Amyloidosis with Apolipoprotein A-IV Deposition.
    Ishimitsu A; Tojo A; Hirao J; Yokoyama S; Ohira T; Murayama Y; Ishimitsu T; Kang D; Honda K; Ehara T; Ishida K; Ueda Y
    Intern Med; 2022; 61(6):871-876. PubMed ID: 35296622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution.
    Chiu A; Dasari S; Kurtin PJ; Theis JD; Vrana JA; Dispenzieri A; Rech KL; Dao LN; Howard MT; Grogan M; McPhail ED
    Amyloid; 2022 Sep; 29(3):156-164. PubMed ID: 35135386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
    Basset M; Nuvolone M; Palladini G; Merlini G
    Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [AL amyloidosis, from diagnosis to treatment].
    Villesuzanne C; Jaccard A; Nicol M
    Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Al amyloidosis.
    Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
    Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
    Madan S; Dispenzieri A; Lacy MQ; Buadi F; Hayman SR; Zeldenrust SR; Rajkumar SV; Gertz MA; Kumar SK
    Mayo Clin Proc; 2010 Mar; 85(3):232-8. PubMed ID: 20194151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
    Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
    Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
    Del Giudice ML; Galimberti S; Buda G
    Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature.
    Sarosiek S; Seldin DC; Connors LH; Spencer B; Murakami A; O'Hara C; Sanchorawala V
    Amyloid; 2015; 22(3):156-62. PubMed ID: 26104853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
    Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
    Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
    Picken MM
    Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.